LeMaitre Vascular (NASDAQ:LMAT) Earns Outperform Rating from Barrington Research

Barrington Research reaffirmed their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research note published on Friday, Benzinga reports. Barrington Research currently has a $92.00 price target on the medical instruments supplier’s stock.

LMAT has been the topic of several other research reports. JMP Securities lifted their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a market outperform rating in a report on Tuesday, August 20th. Roth Mkm reaffirmed a buy rating and issued a $100.00 target price on shares of LeMaitre Vascular in a research note on Friday, May 31st. Roth Capital raised shares of LeMaitre Vascular to a strong-buy rating in a research report on Friday, May 31st. StockNews.com lowered shares of LeMaitre Vascular from a buy rating to a hold rating in a report on Tuesday, August 27th. Finally, Lake Street Capital began coverage on shares of LeMaitre Vascular in a research note on Friday, August 2nd. They set a buy rating and a $105.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $94.40.

LeMaitre Vascular Trading Up 1.6 %

LMAT stock opened at $91.41 on Friday. LeMaitre Vascular has a 1-year low of $44.27 and a 1-year high of $92.90. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 60.54, a price-to-earnings-growth ratio of 2.28 and a beta of 0.88. The company’s 50 day moving average is $86.94 and its 200 day moving average is $78.30.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.37 EPS. As a group, sell-side analysts forecast that LeMaitre Vascular will post 1.85 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.70%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,251 shares of company stock worth $3,714,994. Corporate insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently bought and sold shares of LMAT. Driehaus Capital Management LLC lifted its stake in LeMaitre Vascular by 52.2% in the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after purchasing an additional 90,573 shares during the last quarter. F M Investments LLC bought a new stake in shares of LeMaitre Vascular during the 2nd quarter worth approximately $7,443,000. Congress Asset Management Co. MA boosted its holdings in LeMaitre Vascular by 17.0% during the 4th quarter. Congress Asset Management Co. MA now owns 594,672 shares of the medical instruments supplier’s stock valued at $33,754,000 after acquiring an additional 86,293 shares during the period. Nicholas Investment Partners LP bought a new position in LeMaitre Vascular in the 2nd quarter valued at $3,900,000. Finally, Janus Henderson Group PLC increased its stake in LeMaitre Vascular by 554.7% in the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after purchasing an additional 47,218 shares during the period. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.